Zhejiang Shouxiangu Pharmaceutical , Ltd. EBIT

The latest EBIT for 603896.SS is $-33M as of June 2026. That compares with $150M in the prior-year period — down 121.3% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Zhejiang Shouxiangu Pharmaceutical , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 603896.SS's EBIT moved from $150M to $-33M — a 121.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zhejiang Shouxiangu Pharmaceutical , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 603896.SS currently prints $-33M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Zhejiang Shouxiangu Pharmaceutical , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-33M for 603896.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 603896.SS's EBIT ($-33M), review year-over-year change from $150M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.